INDICATIONS

Mantle Cell Lymphoma

Ibrutinib is indicated for the treatment of patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ibrutinib is indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion

Ibrutinib is indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with 17p deletion.

Waldenstrom’s Macroglobulinemia

Ibrutinib is indicated for the treatment of patients with Waldenstrom’s Macroglobulinemia (WM).

Marginal Zone Lymphoma

Ibrutinib is indicated for the treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.